A Clinical Study to Evaluate the Safety, Tolerability, Dosimetry and Preliminary Efficacy of [177Lu]Lu-XT117 Injection in FAP-positive Patients With Advanced Solid Tumors
Latest Information Update: 17 Jan 2024
At a glance
- Drugs 177LuXT117 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 17 Jan 2024 New trial record